HomeFGEN • NASDAQ
add
FibroGen Inc
Previous close
$8.25
Day range
$8.23 - $8.45
Year range
$4.85 - $21.88
Market cap
34.06M USD
Avg Volume
31.84K
P/E ratio
0.16
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 1.08M | 774.80% |
Operating expense | 5.30M | -43.44% |
Net income | 200.64M | 1,274.41% |
Net profit margin | 18.65K | 234.25% |
Earnings per share | 49.61 | 13,491.78% |
EBITDA | -5.18M | 81.77% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 117.98M | -9.94% |
Total assets | 137.01M | -48.18% |
Total liabilities | 119.53M | -74.36% |
Total equity | 17.48M | — |
Shares outstanding | 4.05M | — |
Price to book | -1.96 | — |
Return on assets | -8.52% | — |
Return on capital | 52.71% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 200.64M | 1,274.41% |
Cash from operations | -1.85M | 77.95% |
Cash from investing | 87.16M | 11,444.37% |
Cash from financing | -85.92M | -67,551.18% |
Net change in cash | -1.87M | 80.78% |
Free cash flow | 72.84M | 1,077.84% |
About
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate. Wikipedia
Founded
Jan 1, 1993
Headquarters
Website
Employees
225
